S
Scholar Rock
Clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a…
About Scholar Rock
Scholar Rock is a biopharmaceutical company focused on developing innovative treatments for diseases by targeting protein growth factors. Operating in the healthcare and biotechnology market, Scholar Rock serves patients and healthcare providers by offering novel therapeutic solutions. The company leverages its unique drug discovery platform to unlock new possibilities in disease treatment, particularly in areas that have been historically overlooked. Scholar Rock's business model revolves around research and development, partnerships, and collaborations with other biopharmaceutical companies and institutions. Revenue is generated through licensing agreements, milestone payments, and eventual product sales. The company is committed to patient-centric approaches and values scientific curiosity and collaboration.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Cambridge, United States
- Listing
- IPO 2018
- Employees
- 351
- Open positions
- 20
- Dealroom signal
- 93.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Scholar Rock.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Mar 2026 | $0 | — | Blue Owl Capital | ↗ |
| POST IPO EQUITYOther financing | Oct 2024 | $300M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $6.5M | — | −$369M | -5674.2% |
| 2025 | $0 | — | −$369M | — |
| 2024 | $0 | — | −$250M | — |
| 2023 | $0 | -100% | −$168M | — |
| 2022 | $33M | +76.4% | −$134M | -404.8% |
| 2021 | $19M | +22.2% | −$127M | -676.5% |
| 2020 | $15M | — | −$87M | -564% |
Growth signals
Latest recorded traffic for Scholar Rock is 20K monthly website visits, up 81.8% over the last three months. Scholar Rock's team grew 5.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A4 investors entered at this stage
ARCH Venture Partners
The Kraft Group
EcoR1 Capital
Fidelity Investments
Series B and later6 investors entered at this stage
Invus
Oxford Finance
Silicon Valley Bank
Redmile Group
Samsara BioCapital
Blue Owl Capital
Other known investors3 additional known investors
Children’s Hospital Boston
Harvard Medical School
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Scholar Rock on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scholar Rock’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.